Think Biotech is a Passing Trend? The FDA Says Otherwise
The FDA’s 2014 guidance agenda indicates a heavy focus on biosimilars
A decade ago, the introduction of standard operating procedures was groundbreaking, but new understanding now helps bring the rigor of QbD to analytical method development.
Looking Back; Moving Forward
I don’t give a d@mn 'bout your bad reputation
Biotech's Uncertain Future
Is the 2013 biotech craze sustainable?